Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
暂无分享,去创建一个
Don M. Benson | C. Hofmeister | H. Kwon | D. Benson | Y. Efebera | G. Starling | A. Rice | Craig C. Hofmeister | Yvonne A. Efebera | Tiffany Hughes | Hakju Kwon | Jianhua Yu | Audie Rice | Gary C. Starling | Shauna M. Collins | Courtney E. Bakan | Gina D. Swartzel | David Ciarlariello | Shakthi Bhaskar | Edward L. Briercheck | Edward L Briercheck | Tiffany Hughes | David Ciarlariello | G. D. Swartzel | C. Bakan | S. M. Collins | Jianhua Yu | Shakthi T Bhaskar | E. Briercheck
[1] M. Baseler,et al. Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay , 2004, Journal of Translational Medicine.
[2] T. Olencki,et al. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay , 2008, Cancer Immunology, Immunotherapy.
[3] A. Fedorov,et al. NTB-A receptor crystal structure: insights into homophilic interactions in the signaling lymphocytic activation molecule receptor family. , 2006, Immunity.
[4] G. Morgan,et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.
[5] M. Caligiuri,et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. , 2011, Blood.
[6] Louis M Weiner,et al. Monoclonal antibodies for cancer immunotherapy , 2009, The Lancet.
[7] M. Caligiuri,et al. Evidence for discrete stages of human natural killer cell differentiation in vivo , 2006, The Journal of experimental medicine.
[8] C. Watzl,et al. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. , 2006, International immunology.
[9] B. Barlogie,et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. , 2008, Blood.
[10] M. Caligiuri,et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.
[11] N. Munshi,et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.
[12] A. Jakubowiak,et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Galateau-Sallé,et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. , 2010, Blood.
[14] S. Jagannath,et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Colonna,et al. The Cytotoxicity Receptor CRACC (CS-1) Recruits EAT-2 and Activates the PI3K and Phospholipase Cγ Signaling Pathways in Human NK Cells1 , 2005, The Journal of Immunology.
[16] A. Rice,et al. HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma. , 2007 .
[17] M. Caligiuri,et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. , 1999, Journal of immunology.
[18] S. Singhal,et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. , 2012, Blood.
[19] M. Caligiuri,et al. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. , 2009, Blood.
[20] J. Sheridan,et al. Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients , 2010 .
[21] F. Zhan,et al. CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.
[22] L. Eisenlohr,et al. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. , 1998, Journal of immunology.
[23] A. Veillette,et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function , 2009, Nature Immunology.
[24] A. Jakubowiak,et al. Monoclonal antibodies in the treatment of multiple myeloma , 2011, British journal of haematology.
[25] M. Caligiuri,et al. The biology of human natural killer-cell subsets. , 2001, Trends in immunology.